Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers
Crossref DOI link: https://doi.org/10.1007/s00280-015-2744-5
Published Online: 2015-05-13
Published Print: 2015-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wainberg, Zev A.
Soares, Heloisa P.
Patel, Ravi
DiCarlo, Brian
Park, David J.
Liem, Andre
Wang, He-jing
Yonemoto, Lisa
Martinez, Diego
Laux, Isett
Brennan, Meghan
Hecht, J. Randolph
Text and Data Mining valid from 2015-05-13